The present invention provides a blood glucose elevation inhibitor having a serine protease inhibitory action, which is a novel therapeutic or prophylactic agent for obesity. A compound represented by the following formula (I)wherein each symbol is as described in the specification, or a pharmaceutically acceptable salt thereof.